Packaging & Labelling
WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility
WuXi Biologics, a global company with leading open-access biologics technology platforms, announced that its robotic aseptic filling isolator facility (DP4) has successfully completed the filling of two batches of pre-filled syringes (PFS).
Using Vanrx SA25 to fill the two batches,...
Press Releases
Hardy Diagnostics announces FDA EUA for antibody test and increases manufacturing capacity for COVID-19 products
Hardy Diagnostics, a medical device manufacturer based in Santa Maria, California, announced FDA EUA approval on April 24th for a new in vitro diagnostic medical device: Anti-SARS-CoV-2 Rapid Test (Cat. No. RTA0203).
This immunoassay is intended for qualitative detection and...
Drug Research
ProteoGenix to accelerate the discovery of SARS-CoV-2 antibodies with first human immune COVID-19 library
ProteoGenix, a global leader in antibody production, is pleased to announce the first Human Immune COVID-19 library for the fast discovery of potent antibodies against SARS-CoV-2.
"Highly sensitive and specific antibodies are critical for the development of diagnostics, therapeutics, and...
Press Releases
Elsevier adds to its extensive free resources for biomedical and scientific researchers working on coronavirus with access to broad suite of tools
Elsevier, a global leader in information analytics specializing in science and health, is offering free access to a unique set of biomedical research tools and content to help researchers and life science companies accelerate efforts to address the current...
Press Releases
Genalyte Announces Availability of its High-Speed COVID-19 Antibody Test
Genalyte, the company empowering physicians and patients with real-time diagnostics and healthcare analytics, announced the availability of its rapid COVID-19 serology panel on its Maverickâ„¢ platform. The panel tests for the detection of IgG and IgM antibodies that the...
Clinical Trials
CTI BioPharma Initiates Phase III Pacritinib Trial in COVID-19
CTI BioPharma Corp. initiated PRE-VENT, a Phase III study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled study, will compare pacritinib plus standard of care (SOC) versus placebo plus standard of care in 358...
Press Releases
Valo Tx Working to Develop Potential COVID-19 Vaccine
Valo Therapeutics Ltd. (Valo Tx), is working to develop a potential novel COVID-19 vaccine with applications across future pandemics. Valo Tx will use its PeptiCRAd technology to coat an (undisclosed) adenovirus vaccine vector, engineered to express coronavirus associated spike...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read